Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Company Deals

MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal

Fineline Cube Jan 10, 2026
Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC

Fineline Cube Jan 11, 2026
Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Fineline Cube Jan 10, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Positive Phase III Results in mCRPC Treatment

Fineline Cube Oct 26, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has released encouraging data from a Phase III study...

Company Drug

Life Molecular Imaging and Sinotau Pharmaceutical Secure NMPA Approval for Neuraceq in China

Fineline Cube Oct 26, 2023

Germany-headquartered Life Molecular Imaging (LMI) and China-based Sinotau Pharmaceutical Group have announced that Neuraceq (florbetaben...

Company Drug

Innovent Biologics’ GFH925 on Track for Priority Review Status for NSCLC Treatment

Fineline Cube Oct 26, 2023

The Center for Drug Evaluation (CDE) has indicated that Innovent Biologics’s (HKG: 1801) Category 1...

Policy / Regulatory

CDE Releases 75th Batch of Generic Reference Preparations with Updated Specifications

Fineline Cube Oct 26, 2023

The Center for Drug Evaluation (CDE) has announced the release of the 75th batch of...

Company Drug

Zhejiang Jianfeng Receives FDA Approval for JFAN-1001 Clinical Trial in NSCLC

Fineline Cube Oct 26, 2023

Zhejiang Jianfeng Group Co., Ltd (SHA: 600668), a leading pharmaceutical company based in China, has...

Company Medical Device

MicroPort CardioFlow Medtech Completes Clinical Implantations of Second-Generation TAVI Device

Fineline Cube Oct 26, 2023

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company Drug

CSPC Pharmaceutical Gains NMPA Approval for Clinical Study of Bispecific Antibody NBL-028

Fineline Cube Oct 26, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Shanghai Henlius Initiates Global Phase III Study for HanSiZhuang in LS-SCLC

Fineline Cube Oct 26, 2023

China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the milestone of the first patient...

Company Deals

Aiolos Bio Inc. Raises USD 245 Million in Series A Funding Led by Top Investors

Fineline Cube Oct 26, 2023

Aiolos Bio Inc., a US-based biotech company, has officially launched with the successful completion of...

Company Drug

Qilu Pharmaceutical Unveils Promising Data for QL1706 in Cervical Cancer Treatment at ESMO 2023

Fineline Cube Oct 26, 2023

China’s Qilu Pharmaceutical showcased compelling data for its combination drug QL1706 (iparomlimab and tuvonralimab) as...

Company

Medytox Shifts Strategy for China Market Entry with Next-Generation Botulinum Toxin

Fineline Cube Oct 26, 2023

Korea-based biopharmaceutical company Medytox has reportedly revamped its strategy for entering the Chinese market, according...

Company Medical Device

MicroPort MedBot’s Toumai Robot Gains NMPA Approval for Endoscopic Surgery

Fineline Cube Oct 26, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252), a leading medical robotics company, has announced...

Company

Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline

Fineline Cube Oct 26, 2023

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has reported its Q3 2023...

Company Deals

AstraZeneca Licenses Nanoform’s Starmap AI Platform to Enhance Drug Development

Fineline Cube Oct 25, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has obtained a license from Finnish drug design...

Company Drug

EC Approves AstraZeneca and Daiichi Sankyo’s Enhertu for Advanced HER2+ NSCLC

Fineline Cube Oct 25, 2023

The European Commission (EC) has granted registration approval for the HER2-directed antibody-drug conjugate (ADC) Enhertu...

Company Drug

Dizal’s Sunvozertinib Shows Promising Efficacy in Advanced NSCLC at ESMO 2023

Fineline Cube Oct 25, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented compelling efficacy and safety data for its...

Company Deals Drug

AbbVie Partners with Lupus Therapeutics to Advance Rinvoq in SLE Treatment

Fineline Cube Oct 25, 2023

AbbVie (NYSE: ABBV) announced this week a strategic collaboration with US-based Lupus Therapeutics aimed at...

Company Drug

BMS’s BMS-986278 Receives FDA Breakthrough Therapy Designation for Pulmonary Fibrosis

Fineline Cube Oct 25, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) announced this week that it has received breakthrough therapy designation...

Company

Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff

Fineline Cube Oct 25, 2023

Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since...

Company Drug

Fosun Pharma Gains NMPA Approval for Phase I Trial of XS-03 in Advanced Solid Tumors

Fineline Cube Oct 25, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...

Posts pagination

1 … 394 395 396 … 606

Recent updates

  • Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal
  • Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC
  • Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D
  • Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy
  • InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Company Drug

Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC

Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.